Skip to main content

Table 1 Baseline characteristics of HCC patients receiving anti-PD-1 blockades

From: Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients

Characteristics Number (%)
Sample size 235
Age, years
  ≤ 50 109 (46.4)
 >50 126 (53.6)
Chronic liver disease
 HBV 203 (86.4)
 None 32 (13.6)
Gender
 Female 31 (13.2)
 Male 204 (86.8)
Vascular invasion
 No 113 (48.1)
 Yes 122 (51.9)
Extrahepatic metastasis
 No 148 (63.0)
 Yes 87 (37.0)
ALBI grade
 I 142 (60.4)
 II 93 (39.6)
AFP reduction> 50%
 No 122 (51.9)
 Yes 113 (48.1)
PIVKA-II reduction> 50%
 No 110 (46.8)
 Yes 125 (53.2)
Baseline AFP level, ng/ml
 Median (range) 2995.0 (25.14–121,000)
  ≤ 400 78 (33.2)
  > 400 157 (66.8)
Baseline PIVKA-II level, mAU/ml
 Median (range) 7209.0 (41–75,000)
  ≤ 400 44 (18.7)
  > 400 191 (81.3)